FindTrial
Sign In

Effects on the clinical evolution of patients with respiratory infection secondary to the Sars-CoV-2 virus, when they are maintaining communication with family/friends through mobile devices compared to patients not having an option of communication

Effects on the clinical evolution of patients hospitalized for respiratory infection secondary to the Sars-CoV-2 virus, when they are maintaining communication with their families through mobile devices

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2020/026
Enrollment
Unknown
Registered
2020-12-21
Start date
2020-12-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

The study will be carried out in the Covid-19 hospitalization area. Patients will be assigned to Groups 1 or 2 alternately, according to the availability of beds. Group 2 patients (Control) will not

Sponsors

Center for Research in Policies, Population and Health (CIPPS), of the Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Men and women • Older than 18 years • Patients with lung infection by the Sars-Cov-2 virus (Covid-19) • With O2 saturation greater than 70% and less than 89% upon admission to the emergency room • Have family or friends to call • The family member or friends have a mobile device to receive video calls

Exclusion criteria

Exclusion criteria: Intubated or with respiratory failure that prevents them from participating • Alterations in the state of consciousness. • Intellectual, verbal, hearing disability • Previous psychiatric or mental disorders (anxiety, depression, bipolar, dementia, etc.) • Voluntary discharge

Design outcomes

Primary

MeasureTime frame
The average number of days of confinement [Measured during the hospital stay up to discharge] Types of complications occurred during the hospital stay [Measured at discharge of patient] Outcome of the disease [Measured at discharge of patient]—

Secondary

MeasureTime frame
The total cost of bed days will be measured + cost of drugs used + cost of laboratory and cabinet tests = Total Cost, for each of the groups [Measured at hospital discharge of patient]—

Countries

American Samoa

Contacts

Public ContactMiguel Angel Fernández Ortega

Researcher from the Center for Research on Population and Health Policies (CIPPS)

miguelaf03@live.com0052 5556 22 1599

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026